ERBB2 and non-small cell lung carcinoma: A major strength of this study was the large number of patients with NSCLC included to estimate the prevalence of common actionable genomic alterations (involving EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, NRAS, and PIK3CA) in Qujing.